

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bob G. Sanders et al.

Serial No.: 10/696,699

Filed: October 29, 2003

For: TOCOPHEROL ASSOCIATED PROTEIN  
AND USES THEREOF

Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: CLFR:226US

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

April 1, 2005

Date

David L. Parker

**INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner. Copies of cited U.S. patents, U. S. patent application publications and co-pending U.S. patent applications have not been enclosed subject to the waiver regarding the requirement under 37 C.F.R. §1.98(a)(2)(i) stated in the Official Gazette Notice dated August 5, 2003 regarding patent applications filed on or after June 30, 2003.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/CLFR:226US.

This application is a continuation-in-part application of Serial No. 10/419,629, filed April 19, 2003 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) only copies of those documents not previously cited and submitted to the Patent and Trademark Office in prior application Serial No. 10/419,629 are enclosed for the convenience of the Examiner.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,  


David L. Parker  
Reg. No. 32,165  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201


Date: April 1, 2005

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.  
CLFR:226USSerial No.  
10/696,699Applicant  
Bob G. Sanders *et al.*Filing Date:  
October 29, 2003Group:  
1614U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1*

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2004/0023915	2/5/04	Sanders <i>et al.</i>	514	44	4/21/03
	A2	2004/0152883	8/5/04	Sanders <i>et al.</i>	536	23.2	10/29/03

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Dutta-Roy <i>et al.</i> , "Purification and partial characterisation of an alpha-tocopherol-binding protein from rabbit heart cytosol," <i>Mol. Cell. Biochem.</i> 123:139-144, 1993.
	C2	Dutta-Roy <i>et al.</i> , "alpha-tocopherol-binding proteins: purification and characterization," <i>Methods Enzymology</i> , 282:278-297, 1997.
	C3	Gordon <i>et al.</i> , "Characterization of a novel alpha-tocopherol-binding protein from bovine heart cytosol," <i>Arch. Biochem. Biophys.</i> , 318:140-146, 1995.
	C4	Sha <i>et al.</i> , "Crystal structure of the <i>Saccharomyces cerevisiae</i> phosphatidylinositol-transfer protein," <i>Nature</i> , 391:506-510, 1998.
	C5	Shibata <i>et al.</i> , "Supernatant protein factor, which stimulates the conversion of squalene to lanosterol, is a cytosolic squalene transfer protein and enhances cholesterol biosynthesis," <i>Proc. Natl. Acad. Sci. USA</i> , 98:2244-2249, 2001.
	C6	Stocker <i>et al.</i> , "Identification of a novel cytosolic tocopherol-binding protein: structure, specificity, and tissue distribution," <i>IUBMB Life</i> , 48:49-55, 1999.
	C7	Zimmer <i>et al.</i> , "A novel human tocopherol-associated protein: cloning, in vitro expression, and characterization," <i>J. Biol. Chem.</i> , 275:25672-25680, 2000.

25516228.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.